Sumitomo Pharma

• NCT05435729

  Phase 1, Completed, 7 people, 28 Jun 2022

• NCT05366868

  Collaborator, Phase 4, Active, not recruiting, 567 people, 9 May 2022

• NCT02358395

  Phase 1, Completed, 12 people, 9 Feb 2015

• NCT02354898

  Phase 1, Completed, 60 people, 3 Feb 2015

• NCT02347917

  Phase 1/2, Completed, 28 people, 28 Jan 2015

• Sustained proton-pump inhibitor exposure and incident age-related macular degeneration: a new-user, population-based cohort study

  Consulting or advice, 23 Sept 2026

• Study Protocol for the TIGHTEN Study Comparing the Effects of Tofogliflozin and Glimepiride on Skeletal Muscle Mass in Patients with Type 2 Diabetes without Obesity: A Prospective, Multicenter, Open-Label, Randomized, Parallel Group Trial in Japan

  Fees or honoraria, 15 Sept 2026

• Distinct metabolomic signatures of SGLT2 inhibitor vs. sulfonylurea in a paired human liver biopsy study

  Fees or honoraria, Grants or research support, 14 Sept 2026

• Tirzepatide Benefit for Early Glycemic and Weight Management in People with T2D in Japan: Rationale, Design, and Baseline Characteristics of T-BEAT Study

  Fees or honoraria, 8 Sept 2026

• Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial

  Fees or honoraria, 17 Aug 2026

• Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial

  Fees or honoraria, 17 Aug 2026

• Clinical efficacy of switching to tirzepatide in patients with type 2 diabetes and a high risk of metabolic dysfunction-associated steatotic liver disease undergoing GLP-1 receptor agonist therapy: Insights from the Hokkaido-TZP study

  Fees or honoraria, 14 Aug 2026

• Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial

  Grants or research support, 13 Aug 2026

• What Should Be Assessed Next After a Positive Screening Test for the Long-Term Care Needs?: A Comparative Analysis of the Clinical Frailty Scale, the Kihon Checklist, and the Dementia Assessment Sheet for Community-Based Integrated Care System-8 Items

  Fees or honoraria, 1 Aug 2026

• The biology of PKM2 in the metabolism and senescence in diabetic kidney disease

  Fees or honoraria, 31 Dec 2025

Sources: pubmed.ncbi.nlm.nih.gov

• SGLT2 Inhibitor Attenuates eGFR Slope in Type 2 Diabetes with UACR <30 mg/gCr

  ADA Scientific Sessions 2026 abstract, 6 Jun 2026

• Five-Year Changes in Glucose Tolerance, Insulin Secretion, and Insulin Resistance in Community-Dwelling Older Adults

  ADA Scientific Sessions 2025 abstract, 13 Jun 2025